Kim Branson

AI in Pharmaceutical R&D with Kim Branson

Kim Branson, Vijay Pande

Kim Branson, GSK's Global Head of AI/ML, is driving a strategic initiative that creates a "sheltered bubble" to rapidly build AI capabilities before integrating them into the company's broader drug discovery workflow. His team currently leverages active learning loops and computational pathology to accelerate target identification and clinical trial optimization, achieving twentyfold reductions in screen times and enabling precise patient stratification. Branson emphasizes that the industry's primary bottleneck is access to longitudinal data with outcomes, positioning GSK to transition from simple algorithmic efficiency to a data-driven "juggernaut" defined by proprietary datasets and mechanistic biological integration.